Abstract: Disclosed are methods for encapsulating pH sensitive cargos, including oxygen binding proteins, in a polydopamine shell.

Abstract: Disclosed are methods for producing matrix-encapsulated proteins, including matrix-encapsulated hemoglobin. Also provided are pharmaceutical compositions comprising a matrix-encapsulated hemoglobin, as well as methods of using thereof to treat hypoxia, cyanide poisoning, hydrogen sulfide poisoning, and/or azide poisoning.

Abstract: Disclosed herein are colloidally stable heme-albumin complexes, as well as compositions comprising these complexes, methods of making these complexes, and methods of using these complexes. These heme-albumin complexes can comprise from three to five heme molecules non-covalently associated with an albumin protein, and a plurality of hydrophilic polymer chains (e.g., polyethylene glycol (PEG) polymer chains) conjugated to the albumin protein.

Abstract: Described herein is a method of preserving a biological tissue sample ex vivo, the method comprising comprises contacting the tissue sample ex vivo with a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.

Abstract: Due to a rising demand in the need for organ transplantation and a critical donor organ shortage, the need to fill this gap has increased the use of ECD and donation after cardiac death (DCD) organs viable for transplantation to lower the mortality of patients on the organ waiting list. Described herein is a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.

Abstract: Methods for removing a contaminate from a blood product and preparing a regenerated blood product from an expired blood product, the methods comprising: filtering the blood product by filtration against a filtration membrane using a low-shear pump, thereby forming a retentate fraction comprising a washed blood product and a permeate fraction comprising the contaminate.

Abstract: Disclosed are methods for producing methemoglobin or polymerized methemoglobin. Also provided are pharmaceutical compositions comprising methemoglobin complexed with haptoglobin or polymerized methemoglobin, as well as methods of using thereof to treat cyanide and hydrogen sulfide poisoning.

Abstract: Disclosed are ocular therapeutic compositions as well as methods for treating ocular diseases and injuries using these compositions.

Abstract: Disclosed are hemoglobin-based oxygen carriers (HBOCs) that comprise a polymer-functionalized polymerized hemoglobin, such as a polyalkylene oxide (PAO)-functionalized polymerized hemoglobin, as well as compositions comprising these HBOCs (e.g., dissolved or dispersed in an aqueous carrier) and methods of making and using thereof.

Abstract: The present disclosure provides methods to diagnose and/or treat hemoglobinopathies via comparative analysis of cell magnetic properties.

Abstract: Disclosed are method of using compositions comprising PolyHSA to preventing, protecting and/or treating conditions such as endothelial dysfunction, and hypercytokinemia.

Abstract: Tangential flow filtration (TFF) is a size-based separation method conventionally used for buffer exchange, concentration, pathogen removal, and for coarse purification. Disclosed herein, TFF was used for selective purification of proteins in their complexed form. In some examples, this process was demonstrated to recover human serum albumin (HSA) in its complexed form from an artificially produced mixture of hemoglobin (Hb) and HSA and from plasma using an anti-HSA polyclonal immunoglobulin G (IgG) as the target-protein binding molecule (TPBM). Moreover, another embodiment of the method recovered haptoglobin (Hp) in its complexed form from human Cohn Fraction IV using Hb as the TPBM. In addition, a mathematical model used to describe the TFF purification process provided that product recovery could be increased without loss of purity by introducing TFF filters with the same MWCO in series.

Abstract: The present disclosure provides methods of treating plasma protein imbalances or depletion (e.g., plasma protein imbalances or depletion caused by hemorrhagic shock or other clinical conditions), in particular by administering protein compositions derived from plasma or plasma isolates.

Abstract: Methods for purifying and isolating extracellular vesicles (EVs) from a biofluid using a sequential processing. Tangential flow filtration is applied to the biofluid to increase the concentration of EVs in the biofluid. After this is achieved, enrichment mode is halted and the biofluid is processed in diafiltration mode to remove contaminants (up to 99.9%). After performing the tangential flow filtration step, the concentration of EVs in the biofluid is further increased by ultracentrifugal filtration. After performing the ultracentrifugal filtration step, EVs of a particular target type are separated from other EVs by immunomagnetic affinity separation. In some implementations, the methods are used to isolate and quantify tumor EVs for cancer evaluation. Additionally, these methods can be used with a scaling factor to quantify EVs from a less concentrated biofluid such as, for example, urine.

Abstract: Disclosed herein are oxygen transporting formulations, in particular those composed of hemoglobin-based nanoparticles, and their use and process of manufacture. These formulations are more uniform and monodisperse than prior hemoglobin-based oxygen carriers, such as polymeric hemoglobin. In addition, these formulations provide higher hemoglobin encapsulation efficiencies and higher hemoglobin content that hemoglobin-containing vesicles.

Abstract: Provided herein are apohemoglobin-haptoglobin complexes as well as apohemoglobin-haptoglobin complexes comprising an active agent coordinated thereto. Methods of using these compositions are also described.

Abstract: Provided herein are methods for purifying proteins from mixtures of proteins using ultrafiltration, such as tangential-flow filtration (TFF). Provided herein are methods for isolating an apoprotein from a protein solution comprising a conjugated protein, wherein the conjugated protein comprises the apoprotein and a hydrophobic ligand associated with the apoprotein.